Janssen's potential "first-in-class" bispecific antibody is clinically approved in China
Innovent and Bolt reached an agreement to jointly develop three anti-tumor drugs using antibody-immune stimulation coupling technology
: The opportunities for listed drugs before 2016 are elusive, and monoclonal antibodies and tinib are still active
The GD2 antibody new drug market application introduced by Saisheng Pharmaceutical is planned to be included in the priority review
Junshi/Lilly's new crown neutralizing antibody cocktail therapy resumes distribution in the United States
neutralizing antibody combination against new coronavirus mutant strains
Novartis terminates phase II study of CD40 monoclonal antibody iscalimab for kidney transplant rejection
First-line treatment of gastric cancer, Zai Lab introduces new monoclonal antibody to treat breakthrough treatment
Fast and sensitive on-site detection technology for new coronavirus antibodies
Dongyang Sun declares PD-1 monoclonal antibody biosimilars
Qilu Pharmaceutical's PD-L1/4-1BB double antibody was approved for clinical use
Semi-annual report of Tianjing Bio: will submit a CD38 antibody listing application and start the research and development of "super antibody"
Clin Cancer Res: Activity and safety of α-PD-L1 antibody ± α-TIM-3 antibody in the treatment of MSI-H/dMMR tumors
Breast cancer antibody treatment pattern: Monoclonal antibody/biantibody/ADC flourishes!
Cinda Biotech declares that the first domestic SIRPα antibody CD47 pathway has deployed 3 new drugs
-spectrum neutralizing antibody combination against the new crown mutant
Is it necessary to carry out antibody testing for people who have been vaccinated?
Cell Res: Broad-spectrum resistance of "public antibodies" to the new coronavirus and its mutants
Survey shows that most Nepalese people have COVID-19 antibodies
The first long-acting preventive new crown antibody combination drug Phase 3 has a positive